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Arterial compliance plays an important role in the proper functioning of the human 
cardiovascular system. Loss of large arterial compliance leads to increased isolated systolic 
hypertension and ventricular hypertrophy1, which results in increased risk of major adverse 
cardiovascular events.1,2 Arterial stiffening occurs as a result of vascular remodeling through 
extracellular matrix (ECM) cross-linking and smooth muscle cell proliferation. Current 
hypertension treatments are only able to treat classical essential hypertension with poor success 
rates in controlling systolic blood pressure.3 There are no targeted treatments available to target 
the age-induced arterial stiffening due to outward vascular remodeling. 
Tissue transglutaminase (TG2) is an important enzyme involved in arterial remodeling with 
a further emerging potential as a therapeutic target for aging induced isolated systolic 
hypertension. TG2 is a multifunctional enzyme with a main crosslinking functionality that 
produces unbreakable “isopeptide” bonds between ECM proteins leading to increased vascular 
stiffness.4,5 While there is substantial evidence that TG2 drives pathobiology of vascular stiffening 
in aging, significant gaps remain in our understanding of the mechanisms of TG2 regulation and 
action in the vasculature. Here, we hypothesize that 1) augmented biomechanical strain is a central 
mechanism contributing to TG2 activation and 2) TG2 crosslinking function is critical to the 
vascular remodeling program. Lack of mouse models and specific inhibitors has hindered our 
ability to study TG2 crosslinking function in vascular biology and disease. Therefore, we generated 
a novel TG2-C277S mutant mouse model that expresses a crosslinking deficient TG2 protein, to 
selectively exclude crosslinking dependent mechanisms of TG2 action in the vasculature.  
 In this study, we found that human aortic endothelial cell secretion of TG2 to the ECM 
peaks at normal physiological stretching (10% strain) and decreases at pathophysiological 
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stretching (20% strain). In human aortic smooth muscle cells, TG2 secretion to the ECM and 
activation proportionally increase due to increased stretching strain. Extending our studies of 
vascular remodeling to our mouse model, we found reduced stiffness initially in the common 
carotid arteries of TG2 C277S and TG2 -/- mice. After hypertensive remodeling, we found that 
TG2 crosslinking is essential to hypertension induced vascular remodeling. We thus suggest that 
in aging isolated systolic hypertension (and increased pulse pressure) increases biomechanical 
strain, activating more TG2 in the tunica media, while decreasing its expression in the intima, 
leading to outward remodeling and vascular stiffening. 
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Heart disease and stroke remain the leading causes of death worldwide, and in the United 
States specifically, they have been the leading causes of death since 1921.8 Hypertension 
specifically has had a continuous increased death rate in the United States,  with an estimated 
31.1% of the world’s population diagnosed with hypertension in 2010.8 In 2015, an estimated 874 
million adults had a systolic hypertension equal to or above 140 mmHg.8 The main culprit of aging 
associated isolated systolic hypertension is arterial stiffening. Left unchecked, arterial stiffening 
increases the risk of a serious adverse cardiac event. 1,2 The gold standard treatment for isolated 
systolic hypertension is to use certain antihypertensive and diuretic drugs combined with lifestyle 
changes in both diet and exercise.3,9 To this day, there are no drugs on the market able to treat the 
arterial stiffening behind isolated systolic hypertension. In order to design a specific therapeutic 
for isolated systolic hypertension due to aging that precisely targets large arterial remodeling, 




Arterial Structure and Compliance 
 
Arteries are composed of a single endothelial cell layer (tunica intima), multiple layers of 
smooth muscle cells with an elastic lamina made up of primarily collagen and elastin (tunica 
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media), and a layer of connective adventitia made up of extracellular matrix (ECM) proteins such 
as collagen, elastin and fibronectin as diagramed below in Figure 1. 
 
Figure 1: Arterial Structure.10 Arteries are comprised of three layers: Tunica Intima (shown in 
deep red), Tunica Media (shown in purple), and Adventitia (shown in bright red/orange). 
(Permission obtained from publisher of citation for use of illustration). 
 
 The main function of arteries is to actively manipulate blood flow to supply oxygen and 
nutrients to specific tissues as necessary. Under short-term changes in blood flow, the smooth 
muscle cell layers within the tunica media contract or relax, which allow for immediate active 
changes in the artery diameter. In response to long term changes in blood flow and blood pressure, 
structural changes in the artery occur changing its compliance. Vessel compliance refers to the 
relationship between the lumen volume of the vessel and the pressure exerted within the lumen. 
The vessel compliance can also be measured and varies when the vessel in a relaxed state (passive 
compliance) or in a contracted state (active compliance).  
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 While arteries must be able to manipulate blood flow to perfuse tissues in a timely manner 
(mostly controlled by smaller resistance arteries), large arteries specifically must be able to 
withstand the high pressures and hoop stress exerted directly after a period of contraction and 
relaxation of the ventricles. Therefore, the compliance of large arteries must have a perfect balance 
for the artery to function properly. If too compliant, the vessel is at risk of bursting and will not be 
able to keep blood flowing effectively. If not compliant enough, the vessel is not able to absorb 
the energy generated from the high pressure exerted during systole, which puts recoil stress back 
onto the heart that eventually leads to ventricular hypertrophy. The ability of large arteries to 
change their structure and modify their compliance is important for proper functioning and 
maintenance of structural integrity over a wide range of operating conditions of hoop stress. 
However, under pathophysiological conditions involved in chronic isolated systolic hypertension, 
the resulting changes can exacerbate the problem. 
 
Hypertension and Vascular Remodeling 
 
 Under chronic hypertensive conditions, arteries are able to adapt their structure 
permanently to withstand the systemic blood flow increase. The vessel’s response, known as 
vascular remodeling, leads to increased stiffness.11 This can occur in three different ways affecting 
all three zones of the arterial structure including intimal hyperplasia, increased medial tone, and 
adventitial fibrosis as seen in Figure 2.10 
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Figure 2: Vascular Remodeling in Arteries.10 All three zones can become thickened due to 
vascular remodeling as seen in the intimal hyperplasia (as the deep red section becomes thickened), 
the increased medial tone (as the purple section becomes thickened) and the adventitial fibrosis (as 
the bright red/orange section becomes thickened). (Permission obtained from publisher of citation 
for use of illustration). 
 
 
 While remodeling occurs in all three zones, the course of vascular remodeling can either 
be directionally outward or inward.11 The endpoint result of remodeling can also differ, either 
being hypotrophic (the overall vessel wall thickness decreases), eutrophic (the overall vessel wall 
thickness stays the same), or hypertrophic (the overall vessel wall thickness increases).11 In the 
presence of increased systolic hypertension and increased pulse pressure due to aging, an outward 
vascular remodeling process occurs with both an increased medial tone and adventitial fibrosis. 
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The resultant remodeling in this case is also hypertrophic, where the vessel over time has an 
increased overall wall thickness. This type of vascular remodeling differs from the inward 
eutrophic remodeling characterized in classical essential hypertension for which current drugs 
treat.11 There is no therapeutic available to stop outward hypertrophic vascular remodeling that can 
ultimately lead all the way to heart failure. Therefore, different molecular targets imperative to this 
process must be explored. 
 
Tissue Transglutaminase Biochemistry 
 
TG2 is a multi-functional enzyme that is shown to be ubiquitously produced in all vascular 
cell types.5,12,13 The three main functions of TG2 include catalytic crosslinking, GDP/GTP binding, 
and fibronectin/collagen binding.14 In the vasculature, the majority of TG2 has been shown to be 
intracellular yet catalytically inactive or in the closed GTP bound conformation as seen in Figure 
3A-B. 12,14,19 When GTP is bound to the enzyme, the active site and active cysteine residue (Cys-
277) is hidden.12 Closed conformation TG2 also exists on the cell surface, where it can mediate 
different binding interactions with ECM proteins such as collagen and fibronectin along with 
integrin. 14 Open conformation TG2 exists in the presence of calcium ions (Ca2+) and is mainly 
secreted into the ECM. 12,14,19,22 In the open conformation, the main TG2 catalytic crosslinking 
activity can either be inactive or active. In oxidative conditions, disulfide bonds between cysteine 
residues will block the active Cys-277 residue.12 In reductive conditions, those disulfide bonds will 
be reduced and the active Cys-277 is available for catalytic crosslinking activity.12  
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Figure 3: Conformations and Functions of TG2.12,14 A) The different functions of TG2 based 
on localization are shown here. B) The three-distinct conformations based on GTP binding and 
Ca2+ concentration are displayed here. (Permission obtained from publisher of citations for use of 
illustrations). 
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TG2 specifically catalyzes the crosslinking of the glutamine side chain to primary amines. 
When the amine donor is a lysine side chain, TG2 creates an isopeptide bond that is stable and 
resistant to proteolytic cleavage as shown in Figure 3A.14 By catalyzing this reaction between 
glutamine and lysine residues on ECM proteins, TG2 is able to establish a stable and highly 
organized ECM. In previous studies, we have shown that TG2 is the predominant transglutaminase 
involved in age related vascular/arterial stiffness, where ECM crosslinking promotes matrix 
deposition/accumulation and thus, increases vessel stiffness.7 We have also previously shown that 
both expression and activity of extracellular TG2 are increased as the vasculature ages.6 
Numerous changes occur in the vascular microenvironment with aging and hypertension 
including loss of NO bioavailability. We have previously shown that in the healthy vessel, normal 
levels of NO S-nitrosylate TG2 and constrain it to the intracellular compartment, thus effectively 
suppressing its crosslinking function.6 In aging and hypertension, loss of NO correlates to reduced/ 
complete loss of TG2 S-nitrosylation, its secretion to and accumulation in the vascular ECM, and 
a striking increase in matrix crosslinking by TG2.6 
 
Biomechanical Regulation of Proteins in Arteries 
 
In human arteries, various mechanical forces are exerted on the different vascular cells 
types. Those include both a shear stress and a normal stress that lead to circumferential stretching 





Figure 4: Biomechanical Stimuli on Arteries.25 In the arteries, there is a wall shear stress exerted 
on the endothelial cell layer, a longitudinal stress and circumferential stress exerted on the 
endothelial and smooth muscle cells in the tunica intima and tunica media. (Permission obtained 
from publisher of citation for use of illustration). 
 
These occur because in each cardiac cycle, the aorta expands during systole to 
accommodate the blood ejected into circulation and to absorb the resultant pressure pulse, and 
recoils during diastole. The pulsatile cyclic stretch exerted on the endothelial cells, smooth muscle 
cells, and fibroblasts occur at a stretching and relaxing frequency of around 1 Hz, assuming that 
the average heart rate is 60-70 beats per minute in a normal adult. The overall strain imposed on 
the cells by the hoop stress is dependent on the pulse pressure of the individual. Pulse pressure is 
defined as the difference between the systolic (ventricle contracting) and diastolic (ventricle 
filling) blood pressures. Chronic increases in pulse pressure due to elevated systolic blood pressure 
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imposes larger than normal cyclic strain on vascular cells. Cells can sense and respond to these 
mechanical forces in the microenvironment. Previously, it has been shown that the key arterial 
cells including fibroblasts, smooth muscle cells, and endothelial cells alter production of various 
structural and signaling molecules as a result of the mechanical stimuli resulting from cyclic 
stretching.15-18 Overall, it is well-accepted that chronic exposure to high pulse pressure stimulates 
pro-fibrotic, matrix depositing pathways, leading to vascular remodeling. Increased wall thickness 
and renormalization of wall stress occur to prevent structural failure of the vessels. Here, we 
propose that TG2, a protein whose primary function is to deposit stable matrices, is activated by 
biomechanical forces in the vascular wall. TG2 regulation due to mechanical stimuli in vascular 
cells has not been studied or characterized, and thus, we wish to explore those aspects of TG2 




The overall goal of this project was to characterize the biomechanical regulation and 
activation of TG2 in large arteries leading to and maintaining arterial stiffening. Arterial stiffening 
and isolated systolic hypertension occur in a positive feedback loop with hypertension promoting 
continued arterial fibrosis and vice versa. Cells within large arteries participate in biomechanical 
sensing, which changes the expression of different proteins. Because of the nuanced bidirectional 
communication between cells and the matrix they reside in, the biomechanical stimuli sensed by 
these cells change because of arterial stiffening, and it is possible biomechanical regulation of TG2 
expression plays an integral role in vascular remodeling. Another important aspect of TG2 
biomechanical regulation and vascular remodeling is what aspect of TG2 function (i.e., 
crosslinking dependent vs crosslinking independent) contributes most to hypertension induced 
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arterial remodeling. To test this, we have created a mouse model expressing TG2 C277S 
catalytically inactive form of TG2. 
 
The main aims/objectives of this project are to:  
1) Characterize the biomechanical regulation of TG2 expression and secretion in-vitro in 
HASMCs and HAECs.  
2) Characterize the biomechanical activation of TG2’s crosslinking function in-vitro in 
HASMCs. 
3) Determine the contribution of TG2’s cross-linking function on loss of large artery 


















TG2 -/- mice on a Black 6/129S mixed background, TGM2 C277S Heterozygous (HET) 
mice on a Black 6 background, TGM2 C277S Homozygous (HOM) mice on a Black 6 background, 
and WT Black 6 littermate mice (to HETs) were used in this study. TG2 -/- mice produce no TG2 
protein, while the TGM2 C277S mice were created using CRISPR-Cas9 gene editing of the TGM2 
gene to introduce a CS mutation at the active site cysteine 277 that abolishes the TG2 cross-
linking activity on one (HET) or both (HOM) alleles, while still producing a properly folded 
molecule recognized through western blotting. Animals were bred in-house, genotyped and 
sequenced accordingly to confirm each animal model. All animals were kept on the same food, 
water, and light exposure cycle. Additionally, all procedures performed on these animals were 
approved by and compliant with the regulations delineated by the Institutional Animal Care and 




For this study, we used a variety of vascular cell types including human aortic endothelial 
and smooth muscle cell primary cell lines. These cell types were cultured using the following 
supplemented media: Human Aortic Smooth Muscle Cells (HASMCs) (ATCC) were cultured with 
complete smooth muscle cell media with 2% FBS, 1% (v/v) penicillin/streptomycin, and Smooth 
Muscle Cell Growth Supplement (ScienCell). Human Aortic Endothelial Cells (HAECs) were 
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cultured using complete endothelial cell media with 5% FBS, 1% (v/v) penicillin/streptomycin, 




Cells were subjected to uniaxial cyclic mechanical stimulation using the Strex Cell 
Stretching System to study the impact of biomechanical strain on Cell morphology and TG2 
expression/secretion/function. Strex chambers were coated with human fibronectin (100 g/mL) 
for 30 minutes at 37C and 5% CO2. The chambers were then washed with 1X PBS three times. 
HASMCs were seeded at a density of 150,000 cells per chamber, while HAECs were seeded at a 
density of 680,000 cells per chamber. After adhesion and growth overnight, the cells were serum 
starved with Insulin-Transferrin-Selenium (ITS) media (DMEM, 1X ITS, P/S) used for HASMCs 
and low serum (0.5% FBS) ECM media used for HAECs for 24 hours. Serum starvation media 
was replaced with fresh ITS or low serum ECM media respectively. The chambers were placed 
into the Strex Cell stretching device and were stretched in a pulsatile manner for 18 hours, set at a 
1 Hz frequency, according to the strain variation described below (0%, 10%, 20%) in 37C and 
5% CO2 conditions. Orientation of the cells was determined with 10x bright-field microscope 
images. The media and cell pellet were then collected for analysis with western blotting. 
 
In Situ TG2 Cross-linking Activity Assay 
 
The incorporation of FITC-conjugated cadaverine, a primary amine and well-known 
substrate of TG2, was determined by fluorescence microscopy to investigate TG2 activity in live 
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cells. Cells were seeded in STREX-mini chambers compatible with IHC procedures. After cell 
seeding and serum starvation for 24 hours, FITC-Cadaverine (100 M, Thermo Fisher Scientific) 
in phenol-red free DMEM media supplemented with ITS was added for the duration of the 
stretching period (18 hours). After incubation, the cells were washed three times with PBS to 
remove excess FITC-cadaverine and fixed with 3.7% formaldehyde for 30 minutes. The cells were 
then blocked with 1% BSA in PBS for 1 hour. Following that, the cells were incubated with mouse 
monoclonal TG2 primary antibody (1:100) followed by DyLight 647 Conjugated Anti-mouse 
secondary antibody (1:200) with appropriate washes in between to label extracellular TG2. The 
nuclei were then stained with DAPI, and the cells were mounted appropriately. Cells were imaged 
at 10x, 20x, and 40x using a Nikon Eclipse 80i fluorescent microscope. The TG2 inhibitor T101 




Abundances of TG2 in the conditioned cell culture media, cell-derived matrix, and cytosol 
were determined using western blotting. GAPDH was used as a loading control where appropriate. 
After equal amounts of protein in all samples were ran through a gel, and transferred appropriately 
onto a nitrocellulose membrane, Ponceau-S staining was used to assess total protein levels on the 
blot. After washing and blocking with 3% Milk in TBST for 1 hour, the blot was incubated with 
TG2 Primary Antibody (1:1000 dilution) for 1 hour. After 3 washes with 1X TBST, the blot was 
then incubated with the appropriate mouse or rabbit HRP conjugated secondary antibody (1:5000 
dilution) for 1 hour. Blots were imaged with Chemiluminescent ECL substrate using a Bio Rad 
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ChemiDoc system. Densitometry analysis was performed on all western blots, where Ponceau-S 
staining for total lane protein or GAPDH was used for normalization. 
 
Open Conformation TG2 Quantification Assay 
 
Abundances of open conformation TG2 in the conditioned cell culture media, cell-derived 
matrix, and cytosol were determined using western blotting after cells were incubated with Biotin-
Ahx-MA-QPL-OMe (B015, 50 M, Zedira). GAPDH was used as a loading control where 
appropriate. After equal amounts of protein in all samples were ran through a gel, and transferred 
appropriately onto a nitrocellulose membrane, a Ponceau-S stain was used to assess total protein 
levels on the blot. After washing and blocking with 3% BSA in TBST for 1 hour, the blot was 
incubated with Streptavidin HRP Secondary Antibody (1:1000 dilution) for 1 hour. After 3 washes 
with 1X TBST, the blots were imaged with Chemiluminescent ECL substrate using a Bio Rad 
ChemiDoc system. Densitometry analysis was performed on all western blots, where Ponceau-S 
staining for total lane protein or GAPDH was used for normalization. 
 
TG2 Activity Assays: We examined TG2 activity in homogenized tissue to determine presence or 
absence of TG2 function in the various mouse models. TG2 Activity was assessed using two 
different crosslinking assays as described below: 
 
Fluorescent Polarization Activity Assay 
 
In this assay, we used the fluorescence polarization resulting from the crosslinking 
of FITC-Cadaverine with N, N-Dimethylcasein due to catalysis by TG2. Liver lysates were 
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obtained from samples from all four of the different animal models. After protein 
quantification, 50 g of protein of protein was loaded into a 96-well black bottom dish in 
a total volume of 100 L (protein in RIPA solution). The Complete N, N-Dimethylcasein 
solution was then prepared in Tris-HCl buffer (pH 8.0, 100 nmol/L) with N, N-
Dimethylcasein at a concentration of 30 mg/mL, CaCl2 at a concentration of 5 mmol/L, 
DTT at a concentration of 10 mM, and FITC-Cadaverine at a concentration of 200 nmol/L. 
100 L of the Complete N, N-Dimethylcasein solution was added to each protein sample 
and mixed thoroughly. RIPA control samples were also prepared to deduce the effects of 
RIPA for the baseline measurement. Lastly, each sample was run in triplicate with both no 
TG2 crosslinking inhibitor, and T101 (10 M). After set up of the plate, the plate was 
incubated at 37C and 5% CO2 overnight. Using the FlexStation 3, a fluorescent 
polarization measurement in RFU’s was obtained using medium sensitivity, a G factor of 
1, and 485 excitation and 515 emission cutoffs. 
 
BPA Incorporation Assay 
 
 Biotinylated pentylamine (BPA) is another amine donor that serves as a small-
molecule substrate of TG2. TG2 activity in-situ or ex-vivo was assessed using a BPA assay. 
EZ Link Pentylamine-Biotin (Thermo Fisher Scientific) was incubated with intact liver 
samples at 37C and 5% CO2 for a four-hour period. After that period, three 1X PBS 
washes were performed and the sample was homogenized to obtain a liver lysate. Protein 
quantification was performed on the lysate, and the samples were used for a dot blot assay. 
The blot obtained was blocked with 1% BSA in TBS for 1 hour and incubated with 
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Streptavidin HRP (1:1000 dilution) at 4C overnight. The blot was imaged with 
Chemiluminescent substrate using the Bio Rad ChemiDoc system. Densitometry analysis 
was performed on the blot and normalized with a Ponceau-S stain.  
 
Tensile Testing of the Aorta 
 
The importance of TG2’s main crosslinking function with age on elastic properties of the 
vasculature was further deduced using tensile testing on wild type, TG2 C277S HET, and TG2 
knockout mice. Aortas were isolated from all three mouse lines, all from ages 10-12 months. They 
were cleaned of any excess fat and placed in Krebs Buffer that contained [in mmol/L] 118.3 NaCl, 
4.7 KCl, 1.6 CaCl2, 1.2 KH2PO4, 25 NaHCO3, 1.2 MgSO4, and 11.1 dextrose with a pH of 7.4. 
The aortas were then cut into 1-2 mm rings for imaging. Bright field microscope images were 
taken (10x, length and lumen images) for both the intact rings. On a puller device (DMT), the pins 
were calibrated and positioned appropriately. Using the DMT 560 software and this calibrated 
puller device, the aortic rings were pulled apart with a displacement velocity of 50 m/s until 
material failure. Using analysis described previously in Steppan et. al, the stress-strain curve 




Pressure myography was used to assess the compliance, stretch, and strain of arteries from 
the different animal models described above both in the absence and presence of calcium, before 
and after remodeling in hypertensive conditions. The carotid arteries were dissected and cleaned 
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of any excess fat. They were then mounted onto steel cannulas in a chamber of the DMT Culture 
Myograph System. Each chamber was filled with Ca2+ free Krebs buffer (containing [in mmol/L] 
118.3 NaCl, 4.7 KCl, 1.2 KH2PO4, 25 NaHCO3, 1.2 MgSO4, and 11.1 dextrose at a pH of 7.4) 
and heated to 37C. Using a peristaltic pump, fresh Ca2+ free Krebs buffer oxygenated with 95% 
O2 and 5% CO2 was used to continuously change the buffer within the chamber. With the DMT 
IR imager, the vessel walls were imaged with the pressure being regulated and set to specific values 
from 50 mmHg to 120 mmHg. Using the DMT Myoview II software, measurements of left wall 
thickness, right wall thickness, average wall thickness, inner diameter, and outer diameter were 
obtained. This was performed in the passive state (no Ca2+) and in the active state (2.5 mM CaCl2). 
After performing pressure-dimension analysis once, phenylephrine at 10-5 M was introduced to 
induce remodeling in Ca2+- containing Krebs buffer and the sample was maintained at 100 mm Hg 
(hypertensive MAP) as a remodeling stimulus. After a 4-hour period, the initial passive and active 
dimension analysis procedure was repeated. To calculate vascular compliance, the following 











All data are displayed as arithmetic mean  standard error of the mean (SEM). Appropriate 
non-parametric tests were used to compare expression values (Kruskal-Wallis Test) since 
normality could not be assumed. Statistical significance was set at P<0.05 for all tests performed, 




Pulsatile Stretching Regulates TG2 Secretion in HASMC 
 
We first investigated the biomechanical regulation of TG2 due to pulsatile cyclic stretch in 
HASMCs. To do this, we utilized the Strex Cell Stretching System, in which HASMCs were 
seeded onto PDMS chambers and mechanically stretched at a controlled frequency and strain. To 
mimic the cell stretching imposed on vascular smooth muscle cells, we stretched the cells with a 
1 Hz frequency for 18 h and varied the strain at 0% (no mechanical stimulation), 10% (normal 
physiological strain in the vessel wall in elastic arteries), and 20% (higher strain associated with 
increased pulse pressure in aging/hypertension). We see that with increasing magnitude of cyclic 
stretching, the HASMC morphology becomes elongated and there is alignment perpendicular with 
the direction of the stretch, thus indicating successful cell stretching. (Figure 5A) The media, cell 
pellet, and cell lysate were collected and processed. After western blotting for TG2, we see that 





Figure 5: Cyclic Stretch of HASMCs Upregulates TG2 Secretion to the ECM. A) Bright-field 
images of the HASMCs after stretching (10x magnification). The perpendicular alignment and cell 
elongation increases as strain increases. B) Media western blots for TG2 Secretion to the ECM, 
TG2 in the Cell Pellet, and TG2 in the Cell Lysate. GAPDH loading Control shown also. TG2 




Next, HASMCs were subjected to the same cyclic stretching at various strains in the 
presence of Biotin-Ahx-MA-QPL-OMe (B015, 50 M, Zedira), an irreversible inhibitor of TG2 
that targets the crosslinking Cys-277 active site when TG2 is in its active and open conformation 
(Figure 6A). This will tell us how much active TG2 is secreted to the ECM. We again saw that 
the total TG2 secretion increases with increasing strain of the cyclic stretch (Figure 5B). However, 
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at 10% strain, the ratio of active, open-conformation TG2 to total TG2 decreases, and at 20% strain 
that ratio increases to a value larger than the static control (Figure 6B).  
After looking at extracellular abundance and conformation of TG2 due to cyclic stretch in 
HASMCs, we next looked at the activity of TG2 cross-linking due to cyclic stretch. During the 
HASMC stretch time period, phenol-red free ITS media with FITC Cadaverine (100 M, Thermo 
Fisher Scientific) was incubated with the cells. FITC Cadaverine is a fluorescently labeled 
molecule that can be catalytically cross-linked to the ECM by TG2. As the strain increases, we see 
that the nuclei orient perpendicular to the stretch, and the increased activity of TG2 seen in the 
increased FITC-Cadaverine incorporation (Figure 6C). TG2 was also stained for and as the strain 
increases, we also see an increase in TG2 present in the cell ECM (Figure 6C).  
 
Figure 6: Cyclic Stretch of HASMCs Activates TG2. A) Flow diagram of use of Zedira 
irreversible inhibitor to test biomechanical strain induced secretion to the ECM and shift to the 
open, active conformation. B) Western blot of open, active conformation TG2 using the Zedira 
irreversible inhibitor. C) FITC incorporation assay images. Nuclei stained with DAPI (blue), 
FITC-Cadaverine incorporation displaying TG2 activity (green), and TG2 expression displayed 
(red). As strain of stretch increases, the TG2 expression in the ECM increases (yellow arrows), 
and the cross-linking activity increases as seen by FITC-Cadaverine incorporation (white arrows). 
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Pulsatile Stretching Regulates TG2 Secretion in HAEC 
 
Next, we extended our study of biomechanical regulation of TG2 to HAECs, another 
relevant vascular cell type. The cell stretching protocol was identical to that of HASMCs, with the 
exception the cell seeding density that differed due to the size and morphology of HAECs. Here, 
after cell stretching, we again see an alignment profile perpendicular to the stretch vector and as 
the magnitude of stretch increases (Figure 7A). The endothelial morphology also becomes more 
elongated compared to the static control as the stretching strain increases, indicating a successful 
stretching of the cells (Figure 7A). The media and cell pellet/lysate were collected and processed, 
and a western blot for TG2 was performed. We see that the secretion of TG2 to the ECM peaks at 
the physiological (10% strain) and decreases at 20% strain but still remains higher than the static 




Figure 7: Cyclic Stretch of HAECs Induces Peak TG2 Secretion at Physiological Strain. A) 
Bright-field image (10x magnification) shows HAEC alignment perpendicular to the axis of stretch 





TG2’s Crosslinking Function Contributes to Aortic Modulus and Loss of Compliance 
 
Recently, our lab has developed a novel TG2 C277S mutant mouse model by CRISPR-
Cas9 mediated editing of the TGM2 gene, that has been by appropriate genotyping and sequencing. 
In this C277S mutant mouse, the active site Cys-277 residue is successfully replaced with a serine 
residue, thus rendering the TG2 molecule catalytically inactive. We successfully generated mice 
that were HET (1 mutant allele, 1 WT allele), HOM (both alleles bear mutation), and WT littermate 
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controls. We first needed to confirm our mouse model on an in-vivo protein level. To do this, we 
isolated liver tissue from TG2 C277S HET, TG2 C277S HOM, and littermate WT mice. TG2 -/-
mice were used as controls to represent complete loss of TG2 protein. The tissue was crushed and 
homogenized appropriately and the lysate was used to examine TG2 expression (western blot) and 
TG2 cross-linking activity (FP assay). The western blot showed expression of TG2 in the TG2 
C277S HET, TG2 C277S HOM, and WT mice, but not in TG2 -/- mice (Figure 8B). The FP TG2 
activity assay showed decreased activity to the TG2 C277S HET mouse, and negligible activity in 
the TG2 C277S HOM and TG2 -/- mice as expected (Figure 8A). These findings confirm that the 
mutation successfully targeted the intended function of TG2.   
 
Figure 8: TG2 C277S CRISPR Mouse Produces Catalytically Inactive TG2. A) FP Assay TG2 
specific activity given as the percent average control. B) Western Blot showing TG2 expression in 
all liver lysates except the TG2 -/- sample, and GAPDH as a loading control. 
 
 After successful confirmation of the reduced activity associated with the TG2 C277S HET 
and HOM mice models, the compliance of the vessels was assessed using pressure myography. 
Starting with passive compliance analysis of the common carotid artery (no muscular contraction), 
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we see that the pre-remodeling compliance plotted as Di2 versus pressure, the compliance varies 
as WT < TG2C 277S HET < TG2 C277S HOM, TG2-/- (Figure 9A). After a four-hour period of 
phenylephrine induced remodeling under constant hypertensive mean arterial pressure (110 
mmHg), the passive compliance analysis was repeated for all samples. We see that while WT show 
a significant reduction in compliance (= increased stiffness), the TG2-/-, HOM, HET do not show 
any significant loss of compliance in remodeling. This is illustrated in the Di2 versus pressure plot 
(Figure 9B). Furthermore, the linear slope of each of the Di2 versus pressure plots for each sample 
were taken to obtain overall compliance of the samples in [m2/mmHg]. Comparing these values, 
we found that the mean compliance of the WT was less than that of the TG2 C777S HET, which 
was less than both the TG2 C277S HOM and TG2 -/- mice (Figure 9C). After hypertensive 
remodeling, we see a greater loss in compliance of the WT samples (P<0.05), with virtually no 





Figure 9: Passive Compliance Analysis After Hypertensive Remodeling. A) Prior to 
remodeling, passive compliance was plotted as Di2 versus pressure, showing the relationship 
between the initial properties of the carotid arteries in the mouse models. B) Passive compliance 
was plotted after the four-hour hypertensive remodeling period. C) The active compliance of each 
sample for each animal model before and after hypertensive remodeling was compared. (N=5 
Animals for Each Condition, *P<0.05).  
  26
After testing passive compliance of the vessels both before and after hypertensive 
remodeling, tensile testing was performed on the intact aortas of the animal models as a measure 
of vessel stiffness. The stress vs. strain relationship (elastic modulus) was obtained from aortic 
rings of the WT, TG2 -/-, and TG2 C277S HET animal models in two different age groups (6-7 
months, 10-12 months). In the 10-12 month old mice, we see a steeper curve in the WT than in the 
TG2 -/- and TG2 C277S HET (P<0.0001: Figure 10A). The TG2 -/- and TG2 C277S HET mice 
appear to be very similar. In the 6-7 month old mice, again we see a steeper curve in the WT mice 
than in the TG2 -/- and TG2 C277S HET (P<0.0001: Figure 10B). Also, again we see that the 
TG2 -/- and TG2 C277S HET curves appear to be very similar. There also is a striking difference 
in the curves looking at age as a factor. In the older mice plots, the stress needed for the 
corresponding strain is less than in the younger aged mice plots (i.e., samples from older mice are 
stiffer). This is true for all animal models. 
 
Figure 10: TG2 Crosslinking Contribution to Elastic Modulus. A) Stress vs. Strain (Elastic 
Modulus) for 10-12 month mice (N=6 Animals For Each Condition, ****P<0.0001). B) Stress vs. 
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Strain (Elastic Modulus) for 6-7 month mice (N=3 Animals For Each Condition, ****P<0.0001). 
C) BPA activity assay showing reduced TG2 activity in the TG2 C277S HET mouse than the WT 
in liver lysate samples. D) Western blot showing TG2 expression in aortic samples for WT and 




Overall vascular stiffness is the sum total of the contributions from the two-primary load-
bearing elements: the vascular ECM and SMC. The passive compliance analysis on the common 
carotid artery and the tensile testing of the aorta help characterize the importance of TG2 
crosslinking on relaxed arterial stiffness (i.e., absence of SMC tone). Next, active (contracted) 
arterial compliance analysis was performed in the same common carotid arteries for each animal 
type. Pre-remodeling, we see the same pattern where the WT plots are below that of the TG2 
C277S HET, which is below the TG2 -/- and TG2 C277S HOM models (Figure 11A). After 
hypertensive remodeling, we again see a loss of compliance in the WT, but not in the TG2 -/-, TG2 




Figure 11: Active Compliance Analysis After Hypertensive Remodeling. A) Prior to 
remodeling, active compliance was plotted as Di2 versus pressure, showing the relationship 
between the initial properties of the carotid arteries in the mouse models. B) Active compliance 
was plotted after the four-hour hypertensive remodeling period. C) The active compliance of each 
sample for each animal model before and after hypertensive remodeling was compared. (N=5 




 In this study, we attempted to further characterize biomechanical TG2 regulation and 
elucidate the importance of TG2’s crosslinking functionality in large artery remodeling. Our 
results indicate that cellular regulation of TG2 secretion to the ECM differ in HAECs and 
HASMCs, potentially indicative of a progressing outward vascular remodeling profile in large 
arteries in the presence of isolated systolic hypertensive conditions. Furthermore, TG2 crosslinking 
directly contributes to the aortic elastic modulus and is essential for vascular remodeling under 
hypertensive conditions. 
 
Cellular Level Biomechanical Regulation of TG2 Suggestive of Outward Arterial Remodeling  
 
 As we age, arterial structure is modified through matrix crosslinking, in which TG2 is a 
major player.6,20,23,26 Initially, in large arteries and the development of classical hypertension, 
intimal hyperplasia occurs leading to a thickened intima layer.23 This stiffening leads to isolated 
systolic hypertension development and an increase in pulse pressure, which simultaneously 
increases hoop stress experienced by cells in the artery. This results in positive feedback loop 
wherein the augmented biomechanical stress promotes an outward remodeling profile, worsening 
the arterial stiffening. With advancing age, the stiffening and hypertension progress to a point that 
the risk of a serious adverse cardiac event becomes imminent.1,2 
Smooth muscle cells in the vessel wall sense and respond to the increased magnitude of 
stretch by depositing additional matrix, by enlarging (hypertrophy), and dividing (hyperplasia). In 
terms of mechanics of the vessel, these cellular events facilitate the thickening of the vessel wall 
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to restore wall stress to levels similar to vascular homeostasis. We predicted that TG2 is a key 
enzyme activated to promote vessel wall remodeling in response to pathological biomechanical 
stress. In our cellular level regulation experiments, we studied how the change in the magnitude 
of biomechanical stimulation of cells within large arteries could affect the expression and 
activation of TG2 crosslinking and how it relates to the remodeling pattern occurring. In the vessel 
wall, endothelial and smooth muscle cells express high levels of TG2 at basal conditions. Thus, 
we focused our efforts on these two cells types. 
 In HAECs, we found an increase in TG2 secretion to the ECM from static conditions to 
exposure to cyclic stretch at 10% strain (normal physiological conditions). The expression of TG2 
was highest at physiological stretch. We suggest that this peak in TG2 secretion from endothelial 
cells under normal physiological conditions compared to static conditions is consistent with the 
need of the tunica intima endothelial layer to be a strong and selective barrier. Surprisingly, and 
contrary to our expectation, we found a decrease in TG2 secretion to the extracellular space at 
pathophysiological conditions (20% strain). The loss of extracellular TG2 in HAEC at pathological 
stretch (when compared to physiologic stretch) could be due to EC responses to promote cell 
adhesion at this high strain by retaining TG2 at the cell surface rather than releasing it to the matrix, 
therefore leading to decreased cell proliferation, or reduced cell viability. The specific mechanistic 
cause for this observation remains to be verified in further studies.  
The HASMCs, on the other hand, continue to increase TG2 secretion with increasing 
magnitude of strain in a linear fashion. Intriguingly, we observed that while TG2 abundance in the 
extracellular space increased with strain, crosslinking function was only markedly increased at 
pathological (20%) strain. We thus predicted that in the case of SMCs, mechanical forces facilitate 
a conformation change in TG2 from closed to open, unmasking its active site cysteine. We tested 
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this hypothesis using the irreversible TG2 inhibitor (Biotinylated-Ahx-MA-QPL-OMe) that binds 
to open conformation of TG2 and traps it in the open conformation. Indeed, the open conformation 
or catalytically active TG2 declines at physiological strain (10%) compared to the static control 
but increases at the pathophysiological strain from increased pulse pressure (20%), suggesting that 
pathological mechanical forces activate TG2 in the vascular media. Importantly, this finding is 
consistent with other studies that show TG2 to be the primary mediator of matrix deposition in the 
early phase of remodeling.24 
Based on these findings, we suggest that as the pulse pressure begins to rise as we age, we 
see an upward shift in the expression and activation of TG2, prominently in the HASMCs and less 
so in the HAECs. This points towards a remodeling of the tunica media and elastic lamina as a 
function of pulse pressure increase. The mechanical regulation of TG2 secretion on the cellular 
level confirms the importance of TG2 in the outward hypertrophic remodeling associated with 
isolated systolic hypertension, providing evidence strongly in favor of TG2 being a therapeutic 
target for isolated systolic hypertension due to aging. 
 
Importance of TG2 Crosslinking Function to Vessel Compliance and Stiffness 
 
 Next, in this study we characterized the importance of TG2 crosslinking to large artery 
stiffness, compliance, and arterial remodeling. After tensile testing of the intact aortas from the 
WT, TG2 -/-, and TG2 C277S HET mouse models, we see that WT vessels are remarkably stiffer 
than the TG2 -/- and TG2 C277S HET vessels. The TG2 -/- and TG2 C277S HET have relatively 
the same stiffness. Previously, our lab has shown a difference in aortic stiffness in WT and TG2 -
/- mice, so that difference seen above is as expected.7 The TG2 C277S HET mouse has one WT 
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TG2 allele and one C277S TG2 mutant allele. The activity was shown to be reduced, but not 
abolished as in the TG2 -/- mice, which is seen in the BPA and FP activity assays performed on 
the mouse models. We thus expected that the mechanical modulus of the HET mice would be 
intermediate to WT and TG2-/-. Surprisingly, however, the TG2 C277S HET aortic stiffness is 
relatively the same as the TG2 -/-, and is much less stiff than the WT, despite the presence of TG2 
crosslinking function. Akker et. al determined that TG2 secretion outside of the cell most likely 
occurs through the production of a micro particle vesicle system, which eventually gets transported 
to the cellular membrane.25 They found in their study that a minimum threshold of TG2 cross-
linking activity is needed for the TG2 to be secreted from the cell membrane.22 This would explain 
our results in this case of the TG2 C277S HET mutant mouse, as the activity is reduced by about 
a factor of 2, which might not be enough to meet the threshold for TG2 secretion to the ECM. This 
would explain the less stiff vessels we see in the results of our study. This remains to be confirmed 
in further studies.  
 After determining the decreased stiffness of the aortas of TG2 -/- and TG2 C277S HET 
mice, we next performed pressure myography to determine the compliance of common carotid 
arteries from the mouse models. Looking at the passive carotid artery compliance using pressure 
myography, we see that initially there is a modest difference in vessel compliance. The TG2 -/- 
and TG2 C277S HOM mice were more compliant than the TG2 C277S HET mice, which was 
more compliant than the WT mice. This is consistent with our findings that TG2 -/-, TG2 C277S 
HOM, and TG2 C277S HET are less stiff than WT aortas. However, the differences in this case 
are not as large as in the aorta, as there is a minimal difference in common carotid artery 
compliance initially. The key difference occurs after phenylephrine induced remodeling under 
hypertensive conditions (110 mmHg consistent pressure). There is a significant loss of compliance 
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in the WT vessels, with no loss of compliance in the TG2 -/-, TG2 C277S HOM, and TG2 C277S 
HET vessels. This suggests that TG2 crosslinking is solely responsible for the loss of compliance 
during this remodeling period. In the active compliance analysis, we see the exact same trend as 
in the passive compliance analysis. The only difference is that the loss of compliance in the WT 
vessels appears to be larger in the contracted state rather than the relaxed state of the vessel. The 
increased loss of compliance during contracted analysis is indicative of the potential addition of 
more smooth muscle cells. This suggests that TG2 crosslinking is necessary for smooth muscle 
cell migration. Overall, the large artery analysis of compliance and stiffness in these animal models 
proves that TG2 crosslinking is essential for isolated systolic hypertension induced remodeling. In 
this study, we used a 4 h remodeling period, which is sufficient to study the initial vessel response. 
Experiments in which the remodeling stimulus is maintained for longer duration (24-48 h) would 




In this study, we demonstrated that TG2 abundance is intimately linked to biomechanical 
strain in both a cellular and physiological level. We further show that different cell types have 
distinct responses to increasing magnitudes of strain ranging from static to hypertensive, likely 
due to the distinct roles these cells play in vascular homeostasis and pathobiology. We also showed 
that TG2 crosslinking function plays a central role in basal aortic stiffness. We finally showed 
using novel mouse models that ablation of TG2 crosslinking function prevents biomechanical 





This study yielded some surprising findings that can be further pursued to obtain 
mechanistic insights on TG2 regulation and vascular stiffening. Specifically, the HAEC show a 
peak secretion of TG2 at physiological stretch and a decline in TG2 secretion in pathological 
conditions. The specific mechanisms leading to this could include 1) retention of TG2 at the cell 
surface to promote EC adhesion, 2) transcriptional regulation of TG2 in ECs, 3) reduced cell 
proliferation in response to pathological strain, or 4) increased cell death/reduced viability in 
response to pathological strain. Moreover, ECs are also continuously exposed to shear stress due 
to the flow of blood. The combined effects of stretch and shear can further alter TG2 secretion by 
ECs. 
Next, contrary to our expectation, the HET mice were more similar to the HOM and      
TG2-/- mice, rather than WT mice. The possible mechanisms include 1) a threshold TG2 activity 
is required to successfully secrete TG2 via exosomes, 2) a small loss in TG2 crosslinking function 
propagates as a high loss in stiffness – this is actually quite intriguing because this suggests that in 
aging and hypertension, a partial inhibition of TG2 may be adequate to preserve vascular 
mechanical properties, or 3) the in the HET mice, the WT allele is somehow silenced either during 
development or postnatally, thus expressing only the mutant version of TG2. This is further 
interesting as this suggests that the mutant TG2 proffers some benefits during growth. Using pulse 
wave velocity measurements, it will be possible to investigate the contribution of TG2 crosslinking 
function to in vivo stiffness. Finally, the specific differences between the HOM and HET mice can 
further be studied in natural aging over the course of the lifetime of the animal, which was outside 
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